Cell and Gene Therapy Catapult
“Our agreement with CGT Catapult is an important strategic step that gives us the flexibility to scale our production capacity, which is crucial to the success of our business both near term, as we prepare for our first clinical trial with QEL-001, and longer term, as we advance our pipeline of novel engineered Treg cell therapies in neuroinflammatory and autoimmune diseases.” “We are thrilled to be part of this consortium to support the continued innovation of cell therapy manufacturing process
Basic Information
- Category: business
- Founded: 2012
- Website: https://ct.catapult.org.uk/
Documented Facts
- Email: press@ct.catapult.org.uk (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Cell and Gene Therapy Catapult.
- Canonical profile: https://brandsource.ai/brands/cell-and-gene-therapy-catapult
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/cell-and-gene-therapy-catapult/json-ld
- Citation profile API: https://brandsource.ai/api/brands/cell-and-gene-therapy-catapult/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (81/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
“Our agreement with CGT Catapult is an important strategic step that gives us the flexibility to scale our production capacity, which is crucial to the success of our business both near term, as we prepare for our first clinical trial with QEL-001, and longer term, as we advance our pipeline of novel engineered Treg cell therapies in neuroinflammatory and autoimmune diseases.” “We are thrilled to be part of this consortium to support the continued innovation of cell therapy manufacturing process
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.